SPR
Basic information
Region (hg38): 2:72887382-72892158
Links
Phenotypes
GenCC
Source:
- dopa-responsive dystonia due to sepiapterin reductase deficiency (Definitive), mode of inheritance: AR
- dopa-responsive dystonia due to sepiapterin reductase deficiency (Moderate), mode of inheritance: AD
- dopa-responsive dystonia due to sepiapterin reductase deficiency (Strong), mode of inheritance: AR
- dopa-responsive dystonia due to sepiapterin reductase deficiency (Strong), mode of inheritance: AR
- dopa-responsive dystonia due to sepiapterin reductase deficiency (Supportive), mode of inheritance: AR
- BH4-deficient hyperphenylalaninemia A (Strong), mode of inheritance: AR
- dopa-responsive dystonia due to sepiapterin reductase deficiency (Definitive), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Dystonia, Dopa-responsive, due to sepiapterin reductase deficiency | AR | Biochemical | The condition may be frequently mistaken for nonspecific findings such as idiopathic "cerebral palsy", and many individuals benefit from medical therapy (eg, levodopa/carbidopa, 5-hydroxytryptophan) | Biochemical; Neurologic | 11443547; 7159114; 18502672; 19130291; 20222129; 21431957; 22291068; 22522443; 22018912; 26123188 |
ClinVar
This is a list of variants' phenotypes submitted to
- Dystonic disorder (10 variants)
- Dopa-responsive dystonia due to sepiapterin reductase deficiency (6 variants)
- not provided (4 variants)
- Intellectual disability (1 variants)
- Inborn genetic diseases (1 variants)
- SPR-related disorder (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the SPR gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 83 | 85 | ||||
missense | 77 | 81 | ||||
nonsense | 9 | |||||
start loss | 2 | |||||
frameshift | 6 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 3 | |||||
splice region | 2 | 3 | 5 | |||
non coding | 13 | 17 | 35 | |||
Total | 15 | 8 | 92 | 100 | 6 |
Highest pathogenic variant AF is 0.0000591
Variants in SPR
This is a list of pathogenic ClinVar variants found in the SPR region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
2-72887393-C-G | Dopa-responsive dystonia | Uncertain significance (Jun 14, 2016) | ||
2-72887419-CGGA-C | Dystonic disorder | Uncertain significance (Feb 22, 2022) | ||
2-72887420-G-A | Dopa-responsive dystonia due to sepiapterin reductase deficiency | Uncertain significance (Jul 01, 2024) | ||
2-72887426-C-G | Dopa-responsive dystonia due to sepiapterin reductase deficiency | Benign/Likely benign (Oct 08, 2021) | ||
2-72887429-G-C | Dopa-responsive dystonia due to sepiapterin reductase deficiency | Uncertain significance (Jan 12, 2018) | ||
2-72887433-A-C | Dopa-responsive dystonia due to sepiapterin reductase deficiency | Likely pathogenic (Mar 01, 2022) | ||
2-72887433-A-G | Dopa-responsive dystonia due to sepiapterin reductase deficiency | Likely pathogenic (Mar 26, 2024) | ||
2-72887436-G-T | Likely pathogenic (Jun 02, 2022) | |||
2-72887438-G-A | Dystonic disorder | Likely benign (Oct 17, 2023) | ||
2-72887437-A-AGGGCGGGCTG | Dystonic disorder | Pathogenic (Oct 22, 2023) | ||
2-72887441-C-T | Dystonic disorder | Likely benign (Nov 21, 2023) | ||
2-72887442-G-A | Dopa-responsive dystonia due to sepiapterin reductase deficiency | Uncertain significance (Jan 22, 2021) | ||
2-72887443-G-T | Dystonic disorder | Uncertain significance (Oct 19, 2021) | ||
2-72887447-G-A | Dystonic disorder | Likely benign (Jan 11, 2024) | ||
2-72887448-G-C | Dystonic disorder • Dopa-responsive dystonia due to sepiapterin reductase deficiency | Uncertain significance (Apr 04, 2022) | ||
2-72887449-G-GGGGGCGGGCT | Dopa-responsive dystonia due to sepiapterin reductase deficiency | Likely pathogenic (Jan 01, 2015) | ||
2-72887455-C-T | Dopa-responsive dystonia due to sepiapterin reductase deficiency • Dystonic disorder | Uncertain significance (Dec 02, 2021) | ||
2-72887456-T-G | Dystonic disorder | Likely benign (Feb 19, 2023) | ||
2-72887459-G-A | Dystonic disorder | Likely benign (Apr 13, 2023) | ||
2-72887460-T-C | Dopa-responsive dystonia due to sepiapterin reductase deficiency | Uncertain significance (Aug 20, 2020) | ||
2-72887470-C-T | Dystonic disorder | Uncertain significance (Apr 20, 2022) | ||
2-72887471-C-G | Dystonic disorder | Likely benign (Dec 11, 2023) | ||
2-72887471-C-T | Dystonic disorder | Likely benign (Dec 12, 2023) | ||
2-72887471-CG-C | Dopa-responsive dystonia due to sepiapterin reductase deficiency | Likely pathogenic (May 30, 2021) | ||
2-72887471-C-CG | Dystonic disorder | Pathogenic (Sep 19, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
SPR | protein_coding | protein_coding | ENST00000234454 | 3 | 4799 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.0434 | 0.858 | 125722 | 0 | 25 | 125747 | 0.0000994 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.733 | 100 | 123 | 0.814 | 0.00000667 | 1607 |
Missense in Polyphen | 36 | 44.213 | 0.81424 | 551 | ||
Synonymous | 1.17 | 49 | 60.6 | 0.809 | 0.00000362 | 591 |
Loss of Function | 1.35 | 3 | 6.80 | 0.441 | 3.74e-7 | 77 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000208 | 0.000208 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.0000544 | 0.0000544 |
Finnish | 0.0000924 | 0.0000924 |
European (Non-Finnish) | 0.0000967 | 0.0000967 |
Middle Eastern | 0.0000544 | 0.0000544 |
South Asian | 0.000257 | 0.0000980 |
Other | 0.000326 | 0.000326 |
dbNSFP
Source:
- Function
- FUNCTION: Catalyzes the final one or two reductions in tetra- hydrobiopterin biosynthesis to form 5,6,7,8-tetrahydrobiopterin.;
- Disease
- DISEASE: Dystonia, DOPA-responsive, due to sepiapterin reductase deficiency (DRDSPRD) [MIM:612716]: A form of DOPA-responsive dystonia. In the majority of cases, patients manifest progressive psychomotor retardation, dystonia and spasticity. Cognitive anomalies are also often present. The disease is due to severe dopamine and serotonin deficiencies in the central nervous system caused by a defect in BH4 synthesis. Dystonia is defined by the presence of sustained involuntary muscle contractions, often leading to abnormal postures. {ECO:0000269|PubMed:11443547, ECO:0000269|PubMed:16650784, ECO:0000269|PubMed:17159114}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Folate biosynthesis - Homo sapiens (human);Sepiapterin reductase deficiency;Segawa syndrome;Pterine Biosynthesis;Dopa-responsive dystonia;Hyperphenylalaniemia due to guanosine triphosphate cyclohydrolase deficiency;Hyperphenylalaninemia due to 6-pyruvoyltetrahydropterin synthase deficiency (ptps);Hyperphenylalaninemia due to dhpr-deficiency;tetrahydrobiopterin <i>de novo</i> biosynthesis;Metabolism of nitric oxide;Folate metabolism;eNOS activation;eNOS activation and regulation;Metabolism;Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation;Metabolism of cofactors;Metabolism of vitamins and cofactors
(Consensus)
Recessive Scores
- pRec
- 0.228
Haploinsufficiency Scores
- pHI
- 0.151
- hipred
- N
- hipred_score
- 0.208
- ghis
- 0.466
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- S
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.992
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Spr
- Phenotype
- homeostasis/metabolism phenotype; growth/size/body region phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan);
Gene ontology
- Biological process
- tetrahydrobiopterin biosynthetic process;nitric oxide biosynthetic process;regulation of nitric-oxide synthase activity;cofactor metabolic process;oxidation-reduction process
- Cellular component
- nucleoplasm;cytosol;extracellular exosome
- Molecular function
- aldo-keto reductase (NADP) activity;sepiapterin reductase activity;NADP binding